<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04682301</url>
  </required_header>
  <id_info>
    <org_study_id>RG1121165</org_study_id>
    <secondary_id>NCI-2020-08393</secondary_id>
    <secondary_id>10557</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <nct_id>NCT04682301</nct_id>
  </id_info>
  <brief_title>Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV</brief_title>
  <official_title>Tailoring Shared Decision Making for Lung Cancer Screening in Persons Living With HIV (PLHIV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study tailors a shared decision making intervention for lung cancer screening in persons&#xD;
      living with human immunodeficiency virus (HIV). Information collected in this study may help&#xD;
      doctors better understand how to perform lung cancer screening in persons living with HIV, so&#xD;
      as to enhance shared decision making in persons living with HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining&#xD;
      potential methods of shared decision making (SDM).&#xD;
&#xD;
      AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback.&#xD;
      Participants may attend a telephone interview over 45 minutes 1 month later.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 5, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Focus group analysis (Aim I)</measure>
    <time_frame>10 months</time_frame>
    <description>All focus groups will be recorded and transcribed. Will use a framework analysis approach which combines both inductive and deductive methods where generated themes are mapped onto an implementation framework, specifically the Tailored Implementation of Chronic Diseases (TICD) checklist. Codes will then be analyzed through a constant comparison method to determine key themes. Will analyze all focus groups in real time to make iterative changes to the focus group guide based on feedback and refining potential methods of shared decision making (SDM). Pre-/post-SDM survey data will be collected via tablet, with a paper option if desired.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung cancer screening knowledge (LKS) responses (Aim II)</measure>
    <time_frame>14 months</time_frame>
    <description>Pre- and post-intervention LKS responses will be compared via Chochran-Mantel-Haenszel or Friedman test based on data type. A Chochran-Mantel-Haenszel test will be used with categorical data and a Friedman test will be used with non-categorical data.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decision of cancer screening (DCS) (Aim II)</measure>
    <time_frame>14 months</time_frame>
    <description>The DCS will be summarized as the median of scores for participants from 0 (extreme certainty) to 100 (extreme uncertainty).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Acceptability of Intervention Measure (AIM) (Aim II)</measure>
    <time_frame>14 months</time_frame>
    <description>Will be summarized and presented as range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intervention Appropriateness Measure (Aim II)</measure>
    <time_frame>14 months</time_frame>
    <description>Will be summarized and presented as range of scores from 1 (low acceptability/appropriateness) to 5 (high acceptability/appropriateness).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fidelity (Aim II)</measure>
    <time_frame>14 months</time_frame>
    <description>Will be summarized as median percent of checklist items completed. Joint displays consistent with a mixed-methods convergent design will be used to analyze and interpret the data.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">263</enrollment>
  <condition>Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
    <description>AIM I: Participants attend a focus group over 1-1.5 hours providing feedback on refining potential methods of SDM.&#xD;
AIM II: Participants receive the SDM intervention developed in Aim I and provide feedback. Participants may attend a telephone interview over 45 minutes 1 month later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Intervention</intervention_name>
    <description>Receive SDM intervention</description>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
    <other_name>Behavior Conditioning Therapy</other_name>
    <other_name>Behavior Modification</other_name>
    <other_name>Behavior or Life Style Modifications</other_name>
    <other_name>Behavior Therapy</other_name>
    <other_name>Behavioral Interventions</other_name>
    <other_name>Behavioral Modification</other_name>
    <other_name>Behavioral Therapy</other_name>
    <other_name>Behavioral Treatment</other_name>
    <other_name>Behavioral Treatments</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discussion (focus group)</intervention_name>
    <description>Attend focus group</description>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
    <other_name>Discuss</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discussion (feedback on SDM)</intervention_name>
    <description>Provide feedback on SDM</description>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
    <other_name>Discuss</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Interview</intervention_name>
    <description>Attend a telephone interview</description>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (focus group, interview)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        PLHIV enrolled in the local University of Washington (UW) HIV cohort and primary providers&#xD;
        at Madison Clinic&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AIM I: PLHIV enrolled in the local UW HIV cohort and primary providers at Madison&#xD;
             Clinic&#xD;
&#xD;
          -  AIM I: Using proposed United States Preventive Services Task Force (USPSTF)&#xD;
             guidelines, participants enrolled in the registry who are current or former smokers,&#xD;
             and report &gt;= 20 pack-years smoking history (n=165) will be eligible for recruitment&#xD;
&#xD;
          -  AIM I: Clinicians (medical doctors, physicians assistants and nurse practitioners) who&#xD;
             provide primary care for PLHIV (n=48) will be eligible&#xD;
&#xD;
          -  AIM II: PLHIV who are eligible for lung cancer screening (LCS) based on proposed&#xD;
             USPSTF criteria&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those found to be ineligible for LCS on coordinator review&#xD;
&#xD;
          -  Are non-English speaking or have cognitive dysfunction that would prevent&#xD;
             participation in SDM&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Triplette, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>September 30, 2021</last_update_submitted>
  <last_update_submitted_qc>September 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

